

The right treatment at the right time

Swedish company Olink Proteomics' purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide. The company was recently acquired by Summa Equity, a lower mid-market Private Equity firm in the Nordics. Jon Heimer, CEO of Olink Proteomics comments: "We are very happy to have Summa Equity as our new owner. They have shown a deep understanding of our technology and the markets we are addressing."

Based on the pioneering research of Professor Ulf Landegren and his group at Uppsala University, Sweden, Olink was founded in 2004. The company has a successful history of developing molecular technologies, with a broad IP portfolio. Many of these have been commercialised through licensing to industry leading partners. "In Sweden we have teachers' exceptions for university-employed professors. That's very different from most other countries, meaning that the IP is owned by the professors and not by the university," Jon Heimer explains.

Uppsala-based Olink is a leader for analysis of protein biomarkers in the field of precision medicine. Future health will be significantly improved using biomarkers for disease prediction, monitoring and diagnosis of patients with a higher degree of precision. Olink's proprietary Proximity Extension Assay (PEA) technology enables researchers to look at unparallelled

numbers of proteins in one simple experiment allowing all medical fields to gain new insights to drive this important field forward. Jon Heimer adds that Olink is recognised worldwide for this unique and proprietary technology. "If you take an example like multiple sclerosis (MS), that is more like an umbrella diagnosis which is very broad and it's very likely quite heterogeneous, meaning that patients will have different needs in terms of treatment. The goal is to give the right patient the right treatment at the right time."

The team at Olink is dedicated to supporting the research community with a rapidly growing high-quality, validated protein target library which, in the next couple of years, will cover the essential part of the blood proteome. With over a million samples analysed and a team of specialist data scientists, Olink also has the expertise to maximize the success of protein biomarker studies.

Summa Equity, Olink's new owner, through a recent acquisition, focuses on investments in companies that help solve global challenges. They are convinced that the scientific and business opportunities for Olink are enormous, as its technology is radically transforming the market for proteomics, thus enabling improved patient treatment. "This acquisition gives us the opportunity to rapidly expand our geographical reach," says Jon Heimer. The company will also invest very heavily in R&D to ensure it keeps the number one position. "So it requires both competence, network and resources and all of that falls in to place with this transaction with Summa Equity, which has the resources and the capability to be the best possible owner to drive the development of Olink Proteomics rapidly forwards into the future."



Olink Proteomics
Uppsala Science Park
SE-751 83 Uppsala
Sweden
Website: www.olink.com

